254 related articles for article (PubMed ID: 37676985)
1. Trichostatin A for Efficient CRISPR-Cas9 Gene Editing of Human Pluripotent Stem Cells.
Molugu K; Khajanchi N; Lazzarotto CR; Tsai SQ; Saha K
CRISPR J; 2023 Oct; 6(5):473-485. PubMed ID: 37676985
[TBL] [Abstract][Full Text] [Related]
2. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
3. A simple, quick, and efficient CRISPR/Cas9 genome editing method for human induced pluripotent stem cells.
Geng BC; Choi KH; Wang SZ; Chen P; Pan XD; Dong NG; Ko JK; Zhu H
Acta Pharmacol Sin; 2020 Nov; 41(11):1427-1432. PubMed ID: 32555510
[TBL] [Abstract][Full Text] [Related]
4. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
Thamodaran V; Rani S; Velayudhan SR
Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
Zhang Y; Sastre D; Wang F
Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
[TBL] [Abstract][Full Text] [Related]
6. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
7. CRISPR Base Editing in Induced Pluripotent Stem Cells.
Chang YJ; Xu CL; Cui X; Bassuk AG; Mahajan VB; Tsai YT; Tsang SH
Methods Mol Biol; 2019; 2045():337-346. PubMed ID: 31250381
[TBL] [Abstract][Full Text] [Related]
8. Homozygous might be hemizygous: CRISPR/Cas9 editing in iPSCs results in detrimental on-target defects that escape standard quality controls.
Simkin D; Papakis V; Bustos BI; Ambrosi CM; Ryan SJ; Baru V; Williams LA; Dempsey GT; McManus OB; Landers JE; Lubbe SJ; George AL; Kiskinis E
Stem Cell Reports; 2022 Apr; 17(4):993-1008. PubMed ID: 35276091
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Mediated Gene Knockout and Knockin Human iPSCs.
Petazzi P; Menéndez P; Sevilla A
Methods Mol Biol; 2022; 2454():559-574. PubMed ID: 33190185
[TBL] [Abstract][Full Text] [Related]
10. CRISPR Del/Rei: a simple, flexible, and efficient pipeline for scarless genome editing.
Feuer KL; Wahbeh MH; Yovo C; Rabie E; Lam AN; Abdollahi S; Young LJ; Rike B; Umamageswaran A; Avramopoulos D
Sci Rep; 2022 Jul; 12(1):11928. PubMed ID: 35831384
[TBL] [Abstract][Full Text] [Related]
11. Efficient Cas9-based Genome Editing Using CRISPR Analysis Webtools in Severe Early-onset-obesity Patient-derived iPSCs.
Patel A; Iannello G; Diaz AG; Sirabella D; Thaker V; Corneo B
Curr Protoc; 2022 Aug; 2(8):e519. PubMed ID: 35950852
[TBL] [Abstract][Full Text] [Related]
12. Induced Pluripotent Stem Cells in the Era of Precise Genome Editing.
Punetha M; Saini S; Chaudhary S; Yadav PS; Whitworth K; Green J; Kumar D; Kues WA
Curr Stem Cell Res Ther; 2024; 19(3):307-315. PubMed ID: 36880183
[TBL] [Abstract][Full Text] [Related]
13. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-Mediated Genome Editing to Generate Clonal iPSC Lines.
Sanjurjo-Soriano C; Erkilic N; Mamaeva D; Kalatzis V
Methods Mol Biol; 2022; 2454():589-606. PubMed ID: 33755901
[TBL] [Abstract][Full Text] [Related]
15. HDAC inhibitors improve CRISPR-mediated HDR editing efficiency in iPSCs.
Zhang JP; Yang ZX; Zhang F; Fu YW; Dai XY; Wen W; Zhang B; Choi H; Chen W; Brown M; Baylink D; Zhang L; Qiu H; Wang C; Cheng T; Zhang XB
Sci China Life Sci; 2021 Sep; 64(9):1449-1462. PubMed ID: 33420926
[TBL] [Abstract][Full Text] [Related]
16. Genome Editing of Induced Pluripotent Stem Cells Using CRISPR/Cas9 Ribonucleoprotein Complexes to Model Genetic Ocular Diseases.
Getachew H; Chinchilla B; Fernandez-Godino R
Methods Mol Biol; 2022; 2549():321-334. PubMed ID: 34128206
[TBL] [Abstract][Full Text] [Related]
17. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
18. A high efficiency precision genome editing method with CRISPR in iPSCs.
Singh A; Smedley GD; Rose JG; Fredriksen K; Zhang Y; Li L; Yuan SH
Sci Rep; 2024 Apr; 14(1):9933. PubMed ID: 38688988
[TBL] [Abstract][Full Text] [Related]
19. Efficient, footprint-free human iPSC genome editing by consolidation of Cas9/CRISPR and piggyBac technologies.
Wang G; Yang L; Grishin D; Rios X; Ye LY; Hu Y; Li K; Zhang D; Church GM; Pu WT
Nat Protoc; 2017 Jan; 12(1):88-103. PubMed ID: 27929521
[TBL] [Abstract][Full Text] [Related]
20. Efficient Gene Editing of Human Induced Pluripotent Stem Cells Using CRISPR/Cas9.
Yumlu S; Bashir S; Stumm J; Kühn R
Methods Mol Biol; 2019; 1961():137-151. PubMed ID: 30912045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
